Default company panoramic image
1ca3eb91 b18d 4440 808a 57518e4149d4

Transposagen Biopharmaceuticals, Inc

Transposagen Biopharmaceuticals, Inc. (Transposagen), is a privately held biotechnology company that is dedicated to providing unique animal models of human dis

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Lexington, KY, USA
  • Currency USD
  • Employees 12
  • Website transposagenbio.com

Company Summary

Transposagen Biopharmaceuticals, Inc. (Transposagen), is a privately held biotechnology company that is dedicated to providing unique animal models of human diseases for drug discovery and development. The production of animal models is a USD $5 billion/year worldwide market. Transposagen is currently focusing on the genetically modified (GM) rodent model market which is a $1.2 billion market. The GM rodent market is experiencing double digit ann

Team

  • Default avatar
    Eric Ostertag
    CEO

    Dr. Ostertag completed his undergraduate training at the University of Wisconsin where he received a B.S. in Genetics with Honors. He went on to do both M.D. and Ph.D. (Molecular Biology) degrees at the University of Pennsylvania. He later completed a residency program in Clinical Pathology and a Fellowship in Transfusion Medicine at the Hospital of the University of Pennsylvania. He is the founder and CEO of Transposagen. Dr. Ostertag secured g

  • Default avatar
    Joseph Ruiz
    Vice President of R&D

    Dr. Ruiz is a stem cell biologist with over 19 years experience in embryonic, hepatic and adipose stem cell systems. He received his Ph.D. in Biology at the University of California at San Diego and pursued his post-doctoral training at Columbia and Harvard Universities in the fields of embryonic stem cell and developmental biology. At the Indiana University School of Medicine (1999-2006), Dr. Ruiz established a novel stem cell core facility (Ani

  • Default avatar
    Gerald R Walsh
    Vice Prident of Operations

    Mr. Walsh has broad financial and operational experience in high technology industries. From 2006 to 2008 he was division controller for Drug Discovery at Millipore. From 2003 to 2006, he was CFO of Linco Research and from 2001 until 2003, he was CFO of ProteoPlex, a spin-off from Incyte Genomics. In 1996, he co-founded WorkNet Communications, a fixed- wireless telecom Company, was its original Chairman and a Director, and was instrumental in rai

Advisors

  • Default avatar
    Frost, Brown, Todd
    Lawyer
    Unconfirmed
    Default avatar
    Desalvo and Company
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    BGA and sveral other Lexington Residents
    Unconfirmed
    Default avatar
    NIH and Kentucky match funding
    Unconfirmed